Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies

Autor: Felipe Ades, Evandro de Azambuja, Ana Catarina Pinto, Martine Piccart-Gebhart
Rok vydání: 2013
Předmět:
Mastectomy
Segmental -- methods
Oncology
Receptor
ErbB-2
medicine.medical_treatment
Subcutaneous trastuzumab
Mastectomy
Segmental
law.invention
chemistry.chemical_compound
Randomized controlled trial
Trastuzumab
law
Breast Neoplasms -- drug therapy -- genetics -- mortality -- pathology
Antibodies
Monoclonal
Humanized -- administration & dosage
Infusions
Intravenous
HER-2 positive
Randomized Controlled Trials as Topic
Neoplasm Recurrence
Local -- mortality -- pathology -- therapy
Early breast cancer
General Medicine
Middle Aged
Prognosis
Combined Modality Therapy
Treatment Outcome
Docetaxel
Chemotherapy
Adjuvant
Female
medicine.drug
Adult
medicine.medical_specialty
Injections
Subcutaneous
Receptor
ErbB-2 -- drug effects -- genetics -- metabolism
Breast Neoplasms
Antibodies
Monoclonal
Humanized
Disease-Free Survival
Drug Administration Schedule
Clinical Trials
Phase II as Topic
Breast cancer
Internal medicine
Biomarkers
Tumor
medicine
Chemotherapy
Humans
Chirurgie
Adverse effect
Aged
Taxane
Dose-Response Relationship
Drug
business.industry
Intravenous trastuzumab
Adjuvant treatment
Tumor Markers
Biological -- analysis -- genetics
medicine.disease
Survival Analysis
Carboplatin
Surgery
Clinical Trials
Phase III as Topic
chemistry
Neoplasm Recurrence
Local
business
Zdroj: Breast, 22 (S2
ISSN: 0960-9776
DOI: 10.1016/j.breast.2013.07.029
Popis: With the exception of endocrine therapy, no other systemic treatment of patients with breast cancer has reached such a magnitude of beneficial effect as trastuzumab. This targeted agent (monoclonal antibody) is associated with a significant improvement in both disease-free (DFS) and overall survival (OS) in women with HER-2 positive breast cancer when given in combination with or in sequence to adjuvant chemotherapy. This has been confirmed in a recent Cochrane meta-analysis of randomized controlled trials (RCTs), including 6 adjuvant and 2 neoadjuvant studies (NSABP B-31, NCCTG N9831, BCIRG 006, HERA, FinHer, PACS-04, Buzdar and NOAH), with data collection until February 2010. Overall, mortality is reduced by one-third and the risk of relapse by 40%.Concerns regarding cardiac dysfunction are declining, with reports indicating its reversibility in most instances, however truly long term cardiac evaluation is still lacking.Hence, the benefit of trastuzumab could be challenged by cardiac toxicity, in lower-risk patients [T1a,b node-negative (N0) tumors] or those with increased cardiovascular risk (older women and patients with previous significant heart disease/suboptimal left ventricular ejection fraction [LVEF (
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: